Health Boards
Fri-23-06-2017, 12:28 PM
What I found in a recent interview with a researcher in Erasmus MC, who does research is the following.
Basically there are two Interleukins involved in Psoriasis IL-23 and IL-17 , there are more involved, but lets not make it too complex, otherwise I don't understand it anymore.
It appears that IL-23 is more connected to Psoriasis and IL-17 is more connected to Psoriatic Arthritis (PsA)
Looking at Stelara, this is more an IL-23 inhibitor, it blocks the pathway it is said, and
Cosentyx is an IL-17 inhibitor.
If you would use plain Farmers logics, medics can do different reasoning, then if you have P, you should aim for Stelara, if you have PsA you shout aim for Cosentyx.
Btw, Psorinovo (DMF) moderates both IL-23 and IL-17 (and more) so that is why it works for P and PsA, although some medics will state different, basically they don't have the experience but theoretical knowledge.
Another interview, with a dermatologist of the AMC Amsterdam, shows that in a comparison between Enbrel (etanercept) and Remicade (infliximab), the Enbrel is certainly working nicely AND.... does not lead to the forming of anti-bodies, so this means you can stay on using it.
Basically there are two Interleukins involved in Psoriasis IL-23 and IL-17 , there are more involved, but lets not make it too complex, otherwise I don't understand it anymore.
It appears that IL-23 is more connected to Psoriasis and IL-17 is more connected to Psoriatic Arthritis (PsA)
Looking at Stelara, this is more an IL-23 inhibitor, it blocks the pathway it is said, and
Cosentyx is an IL-17 inhibitor.
If you would use plain Farmers logics, medics can do different reasoning, then if you have P, you should aim for Stelara, if you have PsA you shout aim for Cosentyx.
Btw, Psorinovo (DMF) moderates both IL-23 and IL-17 (and more) so that is why it works for P and PsA, although some medics will state different, basically they don't have the experience but theoretical knowledge.
Another interview, with a dermatologist of the AMC Amsterdam, shows that in a comparison between Enbrel (etanercept) and Remicade (infliximab), the Enbrel is certainly working nicely AND.... does not lead to the forming of anti-bodies, so this means you can stay on using it.